Skip to content

Autologous Transobturator Fascia Lata Sling in Treatment of Female Stress Urinary Incontinence

Autologous Transobturator Fascia Lata Sling in Treatment of Female Stress Urinary Incontinence

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05646745
Enrollment
60
Registered
2022-12-12
Start date
2022-01-01
Completion date
2026-01-01
Last updated
2024-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress Urinary Incontinence

Keywords

Autologous, TOT, SUI, Stress

Brief summary

To evaluate the outcome of autologous transobturator fascia lata sling for treatment of female stress urinary incontinence at Al-Azhar university hospitals.

Detailed description

Following induction of anesthesia and administration of perioperative antibiotics, the patient is positioned in the dorsal lithotomy position, sterilization and draping will be done. A sterile 16 French Foley catheter is placed to drain the bladder, following this, injectable normal saline is utilized using 10 cc syringe for hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides. Through incision in the lower lateral aspect of the thigh, 4 cm above the knee, \ 1 cm× \ 5 cm fascial strip is isolated from the fascia lata. Two stay sutures are secured to the corners of the fascial segment on each side. About 1cm skin incision is performed at the thigh fold on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration of the fascial strip.

Interventions

PROCEDUREAutologous Transobturator Fascia Lata Sling

Hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides. Through incision in the lower lateral aspect of the thigh, 4 cm above the knee, \ 1 cm× \ 5 cm fascial strip is isolated from the fascia lata. Two stay sutures are secured to the corners of the fascial segment on each side. About 1cm skin incision is performed at the thigh fold on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration of the fascial strip.

Sponsors

Al-Azhar University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Autologous fascia lata is utilized via transobturator approach

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* Women with genuine stress urinary incontinence. * Mixed urinary incontinence with predominant stress element. * Refractory cases to conservative therapy or patients who are not willing to consider (further) conservative treatment.

Exclusion criteria

* Mixed incontinence with predominant Urge urinary incontinence. * Associated local abnormalities that may affect surgery outcomes (e.g. complete procidentia). * Recent or active urinary tract infection. * Recent pelvic surgery. * Neurogenic lower urinary tract dysfunction. * Previous surgery for stress urinary incontinence. * Pregnancy * Less than 12 months post-partum. * Other gynaecologic pathologies affecting bladder functions ( eg, large fibroids, ovarian cysts) * Genito-urinary malignancy. * Current chemo or radiation therapy.

Design outcomes

Primary

MeasureTime frameDescription
complete cure3 monthsNumber of patients without leakage with cough stress test and the patient is satisfied and on examination there is no leakage with cough test.

Secondary

MeasureTime frameDescription
improvement of SUI3 monthsNumber of patients who report leakage only with severe exertion and using a smaller number of pads per day and she feels that she has improved. On examination there is no stress urinary incontinence.

Countries

Egypt

Contacts

Primary ContactMohamed F Salman, MD
Prof_mohamed_fawzy@yahoo.com00201111788996

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 30, 2026